A pilot study of adalimumab in infliximab-allergic patients

Adrienne Youdim, Eric A. Vasiliauskas, Stephan R. Targan, Konstantinos Papadakis, Andrew Ippoliti, Marla C. Dubinsky, Juan Lechago, Jane Paavola, Jaime Loane, Susie K. Lee, Joanne Gaiennie, Katie Smith, Jason Do, Maria T. Abreu

Research output: Contribution to journalArticle

122 Citations (Scopus)

Abstract

The anti-TNF-α antibody infliximab (Remicade) is highly effective in the treatment of Crohn's disease. A subset of patients experience allergic reactions as a result of antibodies to infliximab (ATIs). The purpose of the current study is to describe the safety and efficacy of adalimumab (Humira) in patients previously allergic or intolerant to infliximab. Adalimumab is an anti-TNF-α agent containing only human peptide sequences. Seven patients have been treated with adalimumab who had experienced immediate- or delayed-hypersensitivity reactions to infliximab and one with infliximab-induced lupus. Except for injection site discomfort, adalimumab was well tolerated without signs or symptoms of allergic reactions. One patient who had previously received pooled human immunoglobulin developed a pruritic rash after each dose of adalimumab. Patients with active disease who had previously experienced a robust response to infliximab responded to adalimumab as reflected by an improvement in Harvey-Bradshaw index and inflammatory markers. Based on these preliminary data, adalimumab may be a safe and effective substitute for infliximab-allergic patients. Individuals who have been exposed to human antibodies may be sensitized to other human antibodies such as adalimumab.

Original languageEnglish (US)
Pages (from-to)333-338
Number of pages6
JournalInflammatory Bowel Diseases
Volume10
Issue number4
DOIs
StatePublished - Jul 1 2004
Externally publishedYes

Fingerprint

Antibodies
Hypersensitivity
Infliximab
Adalimumab
Delayed Hypersensitivity
Exanthema
Crohn Disease
Signs and Symptoms
Immunoglobulins
Anti-Idiotypic Antibodies
Safety
Peptides
Injections
Therapeutics

Keywords

  • Adalimumab
  • Crohn's disease
  • Delayed-type hypersensitivity
  • Immediate-type hypersensitivity
  • Infliximab

ASJC Scopus subject areas

  • Immunology and Allergy
  • Gastroenterology

Cite this

Youdim, A., Vasiliauskas, E. A., Targan, S. R., Papadakis, K., Ippoliti, A., Dubinsky, M. C., ... Abreu, M. T. (2004). A pilot study of adalimumab in infliximab-allergic patients. Inflammatory Bowel Diseases, 10(4), 333-338. https://doi.org/10.1097/00054725-200407000-00002

A pilot study of adalimumab in infliximab-allergic patients. / Youdim, Adrienne; Vasiliauskas, Eric A.; Targan, Stephan R.; Papadakis, Konstantinos; Ippoliti, Andrew; Dubinsky, Marla C.; Lechago, Juan; Paavola, Jane; Loane, Jaime; Lee, Susie K.; Gaiennie, Joanne; Smith, Katie; Do, Jason; Abreu, Maria T.

In: Inflammatory Bowel Diseases, Vol. 10, No. 4, 01.07.2004, p. 333-338.

Research output: Contribution to journalArticle

Youdim, A, Vasiliauskas, EA, Targan, SR, Papadakis, K, Ippoliti, A, Dubinsky, MC, Lechago, J, Paavola, J, Loane, J, Lee, SK, Gaiennie, J, Smith, K, Do, J & Abreu, MT 2004, 'A pilot study of adalimumab in infliximab-allergic patients', Inflammatory Bowel Diseases, vol. 10, no. 4, pp. 333-338. https://doi.org/10.1097/00054725-200407000-00002
Youdim A, Vasiliauskas EA, Targan SR, Papadakis K, Ippoliti A, Dubinsky MC et al. A pilot study of adalimumab in infliximab-allergic patients. Inflammatory Bowel Diseases. 2004 Jul 1;10(4):333-338. https://doi.org/10.1097/00054725-200407000-00002
Youdim, Adrienne ; Vasiliauskas, Eric A. ; Targan, Stephan R. ; Papadakis, Konstantinos ; Ippoliti, Andrew ; Dubinsky, Marla C. ; Lechago, Juan ; Paavola, Jane ; Loane, Jaime ; Lee, Susie K. ; Gaiennie, Joanne ; Smith, Katie ; Do, Jason ; Abreu, Maria T. / A pilot study of adalimumab in infliximab-allergic patients. In: Inflammatory Bowel Diseases. 2004 ; Vol. 10, No. 4. pp. 333-338.
@article{209b55a9d32c4e43ac170e021538f5a2,
title = "A pilot study of adalimumab in infliximab-allergic patients",
abstract = "The anti-TNF-α antibody infliximab (Remicade) is highly effective in the treatment of Crohn's disease. A subset of patients experience allergic reactions as a result of antibodies to infliximab (ATIs). The purpose of the current study is to describe the safety and efficacy of adalimumab (Humira) in patients previously allergic or intolerant to infliximab. Adalimumab is an anti-TNF-α agent containing only human peptide sequences. Seven patients have been treated with adalimumab who had experienced immediate- or delayed-hypersensitivity reactions to infliximab and one with infliximab-induced lupus. Except for injection site discomfort, adalimumab was well tolerated without signs or symptoms of allergic reactions. One patient who had previously received pooled human immunoglobulin developed a pruritic rash after each dose of adalimumab. Patients with active disease who had previously experienced a robust response to infliximab responded to adalimumab as reflected by an improvement in Harvey-Bradshaw index and inflammatory markers. Based on these preliminary data, adalimumab may be a safe and effective substitute for infliximab-allergic patients. Individuals who have been exposed to human antibodies may be sensitized to other human antibodies such as adalimumab.",
keywords = "Adalimumab, Crohn's disease, Delayed-type hypersensitivity, Immediate-type hypersensitivity, Infliximab",
author = "Adrienne Youdim and Vasiliauskas, {Eric A.} and Targan, {Stephan R.} and Konstantinos Papadakis and Andrew Ippoliti and Dubinsky, {Marla C.} and Juan Lechago and Jane Paavola and Jaime Loane and Lee, {Susie K.} and Joanne Gaiennie and Katie Smith and Jason Do and Abreu, {Maria T.}",
year = "2004",
month = "7",
day = "1",
doi = "10.1097/00054725-200407000-00002",
language = "English (US)",
volume = "10",
pages = "333--338",
journal = "Inflammatory Bowel Diseases",
issn = "1078-0998",
publisher = "John Wiley and Sons Inc.",
number = "4",

}

TY - JOUR

T1 - A pilot study of adalimumab in infliximab-allergic patients

AU - Youdim, Adrienne

AU - Vasiliauskas, Eric A.

AU - Targan, Stephan R.

AU - Papadakis, Konstantinos

AU - Ippoliti, Andrew

AU - Dubinsky, Marla C.

AU - Lechago, Juan

AU - Paavola, Jane

AU - Loane, Jaime

AU - Lee, Susie K.

AU - Gaiennie, Joanne

AU - Smith, Katie

AU - Do, Jason

AU - Abreu, Maria T.

PY - 2004/7/1

Y1 - 2004/7/1

N2 - The anti-TNF-α antibody infliximab (Remicade) is highly effective in the treatment of Crohn's disease. A subset of patients experience allergic reactions as a result of antibodies to infliximab (ATIs). The purpose of the current study is to describe the safety and efficacy of adalimumab (Humira) in patients previously allergic or intolerant to infliximab. Adalimumab is an anti-TNF-α agent containing only human peptide sequences. Seven patients have been treated with adalimumab who had experienced immediate- or delayed-hypersensitivity reactions to infliximab and one with infliximab-induced lupus. Except for injection site discomfort, adalimumab was well tolerated without signs or symptoms of allergic reactions. One patient who had previously received pooled human immunoglobulin developed a pruritic rash after each dose of adalimumab. Patients with active disease who had previously experienced a robust response to infliximab responded to adalimumab as reflected by an improvement in Harvey-Bradshaw index and inflammatory markers. Based on these preliminary data, adalimumab may be a safe and effective substitute for infliximab-allergic patients. Individuals who have been exposed to human antibodies may be sensitized to other human antibodies such as adalimumab.

AB - The anti-TNF-α antibody infliximab (Remicade) is highly effective in the treatment of Crohn's disease. A subset of patients experience allergic reactions as a result of antibodies to infliximab (ATIs). The purpose of the current study is to describe the safety and efficacy of adalimumab (Humira) in patients previously allergic or intolerant to infliximab. Adalimumab is an anti-TNF-α agent containing only human peptide sequences. Seven patients have been treated with adalimumab who had experienced immediate- or delayed-hypersensitivity reactions to infliximab and one with infliximab-induced lupus. Except for injection site discomfort, adalimumab was well tolerated without signs or symptoms of allergic reactions. One patient who had previously received pooled human immunoglobulin developed a pruritic rash after each dose of adalimumab. Patients with active disease who had previously experienced a robust response to infliximab responded to adalimumab as reflected by an improvement in Harvey-Bradshaw index and inflammatory markers. Based on these preliminary data, adalimumab may be a safe and effective substitute for infliximab-allergic patients. Individuals who have been exposed to human antibodies may be sensitized to other human antibodies such as adalimumab.

KW - Adalimumab

KW - Crohn's disease

KW - Delayed-type hypersensitivity

KW - Immediate-type hypersensitivity

KW - Infliximab

UR - http://www.scopus.com/inward/record.url?scp=3543075236&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=3543075236&partnerID=8YFLogxK

U2 - 10.1097/00054725-200407000-00002

DO - 10.1097/00054725-200407000-00002

M3 - Article

C2 - 15475739

AN - SCOPUS:3543075236

VL - 10

SP - 333

EP - 338

JO - Inflammatory Bowel Diseases

JF - Inflammatory Bowel Diseases

SN - 1078-0998

IS - 4

ER -